← All trials
NCT05816330
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- May 25, 2023
- Primary completion
- Mar 31, 2024
- Completion date
- Mar 31, 2024
- First posted
- Apr 18, 2023
- Last posted
- Oct 27, 2023
- Enrollment
- 288
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- National Institute of Allergy and Infectious Diseases (NIAID)Lead sponsor
- Faculté de Médecine Pharmacie d'Odontostomatologie (FMOS/FAPH)Collaborator
- Faculté de Médecine Pharmacie d'Odontostomatologie (FMPOS)Overall official - principal investigator
- Indiana UniversityCollaborator
- Malaria Research and Training Center, Bamako, MaliCollaborator
- National Institutes of Health (NIH)Collaborator
- National Institutes of Health (NIH)Overall official - principal investigator
- University of the Sciences, Techniques and Technologies of BamakoCollaborator
- University of WashingtonCollaborator
- National Institutes of Health (NIH)Official
- Faculté de Médecine Pharmacie d'Odontostomatologie (FMPOS)Official
- Harvard UniversityCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.